Samuel Waxman Cancer Research Foundation (SWCRF) to honor Kenneth C. Anderson, M.D., of Dana-Farber Cancer Institute and breast cancer advocate Musa Mayer at May 12 scientific symposium

New York, NY, April 8, 2014 – The Samuel Waxman Cancer Research Foundation (SWCRF) today announced it will recognize the accomplishments of Kenneth C. Anderson, M.D., and Musa Mayer, two leading figures in the worlds of cancer research and patient advocacy, at its scientific symposium to be held May 12 at the Leon and Norma Hess Center for Science and Medicine at Mount Sinai Hospital.

Dr. Anderson, who is Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, will receive the David T. Workman Memorial Award, a biennial recognition bestowed on scientists who develop novel therapies for poorly treatable cancer types. Dr. Anderson is being recognized for his role in research that resulted in the clinical development of more effective non-cytotoxic treatments for multiple myeloma.

Ms. Mayer, a 25-year breast cancer survivor who’s authored three books on breast cancer, will receive the SWCRF Distinguished Service Award, which acknowledges a recipient’s longstanding dedication to championing awareness for quality care for people living with cancer. Ms. Mayer is being honored for her work as a vocal proponent of both quality patient care and research.

“It is a great pleasure to celebrate the contributions of Kenneth Anderson and Musa Mayer, two innovators in the cancer field who have made tremendous impact in their respective areas of research and advocacy,” said SWCRF founder and CEO Samuel Waxman, M.D. “Their combined efforts have enhanced the experience of cancer patients, which is the ultimate goal the cancer research and cancer care communities share.”

The SWCRF’s annual scientific symposium brings together the Institute Without Walls, a network of the foundation’s funded scientists working collaboratively throughout the United States and abroad on research projects that identify and correct abnormal gene function that causes cancer and develop minimally toxic patient treatments. The network includes scientists from leading cancer research institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and Weill Cornell Medical Center, among many others.

About Kenneth C. Anderson, M.D.

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.  After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute.  Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma.  He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies.  His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

About Musa Mayer

Musa Mayer is a 25-year survivor, advocate and author of three books on breast cancer.  Long known for her writing and advocacy on behalf of people living with advanced disease and their families, she is a founding member of the Metastatic Breast Cancer Alliance, a broad collaboration of over 20 support, research and advocacy organizations and industry partners. As a research advocate, she serves on steering and data monitoring committees for a number of clinical trials and patient registries.  She worked for many years as a patient representative with the FDA, as well on a Department of Defense funded Center of Excellence studying brain metastasis, for which she co-developed BrainMetsBC.org, the only resource of its kind. Her patient surveys have been widely used to improve services, and her web course in evidence-based healthcare trains advocates worldwide. Musa's web resource for metastatic breast cancer can be found at AdvancedBC.org.

About Samuel Waxman Cancer Research Foundation

The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients. Through the Foundation’s collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded more than $85 million to support the work of more than 200 researchers across the globe. For more information, visit: www.waxmancancer.org.

Media Contact:

Edgar Trinidad

Director, Marketing & Communications

Samuel Waxman Cancer Research Foundation

646-398-5261

etrinidad@waxmancancer.org